Immunome, Inc.
IMNM
$18.20
-$0.19-1.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 4.02M | 2.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 4.02M | 2.93M |
| Cost of Revenue | 46.38M | 50.77M | 49.19M | 40.45M | 36.87M |
| Gross Profit | -46.38M | -50.77M | -49.19M | -36.44M | -33.95M |
| SG&A Expenses | 12.95M | 12.09M | 10.95M | 10.04M | 10.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.33M | 62.86M | 60.14M | 50.49M | 47.56M |
| Operating Income | -59.33M | -62.86M | -60.14M | -46.48M | -44.64M |
| Income Before Tax | -53.84M | -69.90M | -57.46M | -43.40M | -41.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.84M | -69.90M | -57.46M | -43.40M | -41.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.84M | -69.90M | -57.46M | -43.40M | -41.64M |
| EBIT | -59.33M | -62.86M | -60.14M | -46.48M | -44.64M |
| EBITDA | -58.73M | -62.23M | -59.55M | -45.84M | -44.03M |
| EPS Basic | -0.48 | -0.74 | -0.65 | -0.50 | -0.52 |
| Normalized Basic EPS | -0.30 | -0.39 | -0.41 | -0.31 | -0.33 |
| EPS Diluted | -0.48 | -0.74 | -0.65 | -0.50 | -0.52 |
| Normalized Diluted EPS | -0.30 | -0.39 | -0.41 | -0.31 | -0.33 |
| Average Basic Shares Outstanding | 113.14M | 94.93M | 87.96M | 87.01M | 79.41M |
| Average Diluted Shares Outstanding | 113.14M | 94.93M | 87.96M | 87.01M | 79.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |